DNA Script
Biotechnology company pioneering enzymatic DNA synthesis (EDS) technology, enabling rapid, high-quality DNA synthesis on benchtop instruments for life sciences research and applications.
Notes
DNA Script is a biotechnology company headquartered in Paris, France, with US operations in San Francisco. The company has developed a breakthrough enzymatic DNA synthesis (EDS) technology that enables DNA to be synthesized using enzymes rather than traditional chemical methods.
The company's SYNTAX System is a benchtop instrument that allows researchers to synthesize custom DNA oligonucleotides on-demand in their own laboratories, dramatically reducing turnaround time from days to hours. This technology has applications across life sciences research, diagnostics development, and synthetic biology.
DNA Script has raised significant funding and established partnerships with major research institutions and pharmaceutical companies to advance applications of enzymatic DNA synthesis.
Team
- Thomas Ybert, Ph.D. - Co-founder & CEO
- Sylvain Gariel - Co-founder & COO
- Xavier Godron - Co-founder & CTO
Additional Research Findings
- Portfolio company of Sofinnova Partners
- Founded in 2014 in Paris, France
- Dual headquarters: Paris and San Francisco
- Pioneer in enzymatic DNA synthesis (EDS) technology
- SYNTAX System: benchtop DNA printer
- Raised over $300 million in funding
- Investors include Sofinnova Partners, LSP, Bpifrance, and others
- Applications: research, diagnostics, synthetic biology, drug discovery
- Technology enables same-day DNA synthesis
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Sofinnova Partners | Paris, France | biotech-focused | seedseries-a+3 | 23 |